FibroBiologics (FBLG) announced a significant advancement in neurodegenerative disease research. Leveraging the Cuprizone animal model, ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic ...

A new study reveals that inflammation during pregnancy may impair neurodevelopment in infants by reducing CD11c-positive ...

A precision medicine workflow integrating proteomics and personalized xenograft models was developed and applied to an ...

Researchers at The University of Texas at Dallas have invented a new, inexpensive method for fabricating artificial muscles ...

Prosecutors say they have evidence that the man charged in the stabbing deaths of four University of Idaho students bought a knife and knife sheath online in the months before the killings ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data expected in 2025. Click for my IMVT update.

Microglia dysfunction and cell death in the brain not only paralleled vascular inflammation, but also marked sites of damage to synapses and myelin sheaths that play a crucial role in neuronal ...

Elon Musk has shared a video of re-designed Tesla's new Model Y on X, formerly known as Twitter. The Model Y offers innovative storage solutions with power-reclining seats and an expanded cargo ...

In people with multiple sclerosis (MS), lesions that get slowly bigger over time, potentially due to chronic inflammation, are associated with more myelin loss throughout the brain, a study found.

Just two months after the tech world was upended by the DeepSeek-R1 AI model, Alibaba Cloud has introduced QwQ-32B, an open source large language model (LLM). The Chinese cloud giant describes the ...

Alibaba added the model has achieved a “qualitative leap in mathematics, coding, and general capabilities, with overall performance on par with DeepSeek R1,” it said in the statement.